China's most consequential oncology export may not be a medicine; it may be a new pace of competition. Can Europe still shape innovation that begins somewhere else?

Every time I return from ESMO, one of the most challenging, and most interesting, exercises I undertake is to look beyond the individual readouts and ask what will shape oncology next. This year, China was impossible to treat as a side story. China data appeared across the congress, but one joint ESMO–CSCO session addressed the bigger question directly: what will China's growing role mean for European oncology? Near the end of the session, a representative from a China-based start-up asked a practical question: If early clinical development is faster and less expensive in China than in Europe or the US, is that advantage likely to last? And where should a small Chinese company preparing to take a molecule into the clinic begin? These questions resonated with the attendees because they touched on a genuine tension facing European oncology development today…

Europe wants Chinese companies to include European patients and investigators earlier, particularly regarding dose selection, trial design, comparators and the evidence eventually submitted to European regulators. But it is often a slower and more expensive place in which to begin generating it. China, meanwhile, has built the patient access, clinical infrastructure and industrial confidence to move molecules rapidly from discovery into large, randomised trials; since China-originated molecules are heavily accelerating the time to start a clinical trial, this new approach is changing how fast everyone else will be expected to drive. One speaker described China as “a motor of global development”. This was a good metaphor, but perhaps it didn’t go far enough. It is changing the speed expected of everyone else.

Fig 1: Summary of key timelines in the drug approval process across regions

Source: See references 1-5

Inspiring Better Healthcare

Ipsos Rx Insight Store

Contact us

About the Research

Privacy

Cookie Policy